Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revised IEC EMC Standard To Include More Stringent Pass/Fail Criteria - FDA

This article was originally published in The Gray Sheet

Executive Summary

The International Electrotechnical Commission's revised 60601-1-2 electromagnetic compatibility (EMC) standard will include more rigorous immunity pass/fail criteria than the current version, according to Jeffrey Silberberg, senior electronics engineer in the Office of Science and Technology within the FDA Center for Devices and Radiological Health.

You may also be interested in...



IEC WORKING GROUP WILL CONSIDER CHANGES TO EMC STANDARD FOR MEDICAL DEVICES AT HELSINKI MEETING; FDA's CONCERNS WITH PASS/FAIL CRITERIA TO BE ADDRESSED

An International Electrotechnical Commission working group on electromagnetic compatibility will consider changes being sought by FDA to the IEC 601-1-2 safety standard at a meeting in Helsinki, Finland during the week of May 12.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel